Loss of mobility influences the quality of life for patients with neuromuscular diseases.
Common measures of mobility and chronic muscle damage are the six-minute walk test and
serum creatine kinase. Despite extensive pre-clinical studies of therapeutic approaches,
characterization of these measures is incomplete. To address this, a six-minute ambulation
assay, serum creatine kinase, and myoglobinuria were investigated for the mdx mouse, a
dystrophinopathy mouse model commonly used in pre-clinical studies. mdx mice ambulated …